Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | DHODH | Q02127 | 11/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760125 | 0.83 | DHODH (0.55) | PDE10ATSHRDHODHLMNACYP2D6 | |
| SCHEMBL3322299 | 0.81 | TACR3 (0.53) | TSHRCYP2D6CYP2C19KMT2A | |
| SCHEMBL1581125 | 0.81 | TACR3 (0.53) | TSHRCYP2D6CYP2C19KMT2A | |
| SCHEMBL4760121 | 0.81 | PDE10A (0.59) | PDE10ATSHRDHODHLMNACYP2D6 | |
| SCHEMBL4449047 | 0.80 | LMNA (0.69) | PDE10ALMNAKMT2A | |
| SCHEMBL1581130 | 0.78 | TACR3 (0.73) | TSHRCYP2D6CYP2C19KMT2A | |
| SCHEMBL2010542 | 0.78 | TACR3 (0.73) | TSHRCYP2D6CYP2C19KMT2A | |
| SCHEMBL5046700 | 0.78 | LMNA (0.61) | PDE10ATSHRLMNA | |
| SCHEMBL5029765 | 0.78 | PDE10A (0.56) | PDE10ATSHRDHODHLMNACYP2D6 | |
| SCHEMBL3329491 | 0.77 | TACR3 (0.58) | TSHRCYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | claimed |
| CN-101679271-A | Quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of central nervous system and peripheral diseases | ASTRAZENECA AB | 2010-03-24 | — | — | CN | claimed |
| EP-2137155-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | AstraZeneca AB (SE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008115140-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | claimed |
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | ASTRAZENECA AB (SE) | 2010-05-13 | — | — | US | disclosed |
| EP-2137155-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | AstraZeneca AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008115140-A1 | QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE IN TREATING CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120850-A1 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases | PMP22, RECQL, ACHE | PDE10A 358/4885TSHR 2105/4885DHODH 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.